IFCT-1701 DICIPLE A randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in treatment-naive patients with stage IV Non-Small Cell Lung Cancer (NSCLC) after Nivolumab-Ipilimumab induction treatment

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514586-20-01

Acronym

IFCT-1701

Enrollment

1360

Registered

2025-01-21

Start date

2018-05-02

Completion date

2025-10-15

Last updated

2025-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non small cell lung cancer

Brief summary

Progression Free Survival (PFS1)

Detailed description

Progression Free Survival (PFS2), Quality of life (QoL), Overall survival (OS), Biological correlative exploratory studies (PD-L1), Biological correlative exploratory studies (PD-L1 H score), Biological correlative exploratory studies (CD3/CD8), Biological correlative exploratory studies (neutrophil), Biological correlative exploratory studies (cytokines), Biological correlative exploratory studies (chemokines)

Interventions

DRUGYERVOY 5 mg/ml concentrate for solution for infusion

DRUGOPDIVO 10 mg/mL concentrate for solution for infusion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression Free Survival (PFS1)	—

Secondary

Measure	Time frame
Progression Free Survival (PFS2), Quality of life (QoL), Overall survival (OS), Biological correlative exploratory studies (PD-L1), Biological correlative exploratory studies (PD-L1 H score), Biological correlative exploratory studies (CD3/CD8), Biological correlative exploratory studies (neutrophil), Biological correlative exploratory studies (cytokines), Biological correlative exploratory studies (chemokines)	—

Measure

Time frame

—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026